Innovative Therapeutics Anacor's focus on novel small-molecule therapeutics derived from boron chemistry positions it as a leader in specialized treatments, especially for fungal and inflammatory skin conditions. This innovative approach offers opportunities to collaborate or license similar advanced compounds within the dermatology and infectious disease markets.

Strategic Acquisition Success The company's acquisition by Pfizer for 5.2 billion dollars highlights its valuable pipeline and R&D capabilities. Potential sales opportunities could involve licensing or partnerships for late-stage clinical assets or acquiring similar innovative compounds to expand your portfolio.

Pipeline Strength With multiple clinical-stage programs targeting dermatological and infectious conditions, Anacor presents opportunities for clinical collaboration, co-development, or licensing for products nearing commercialization that align with emerging market needs.

Focused Market Position Operating with a relatively small but specialized team, Anacor's niche focus allows for tailored outreach to niche dermatology and infectious disease markets, presenting potential for targeted sales of complementary products or services within this space.

Financial and Growth Potential While the company has modest revenue in the range of 25 to 50 million dollars, its substantial funding suggests capacity for growth and expansion. This indicates a potential opportunity for strategic partnerships to accelerate development, distribution, and market entry for its key pipeline candidates.